Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.

Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

Iraqi Journal of Hematology is a prominent peer-reviewed open-access journal dedicated to advancing the field of hematology. Published by Wolters Kluwer Medknow Publications, this journal provides a platform for researchers, professionals, and students to share cutting-edge findings and developments in various aspects of hematology, including blood diseases, diagnostics, and innovative treatments. Since its transition to open access in 2016, the journal has significantly increased its reach, allowing for wider dissemination of critical research to a global audience. With an ISSN of 2072-8069 and an E-ISSN of 2543-2702, the Iraqi Journal of Hematology strives to adhere to the highest scholarly standards and plays a vital role in the ongoing discourse in hematological research. Researchers are encouraged to contribute to this essential resource for the scientific community, contributing to the advancement of knowledge that ultimately improves patient care and treatment outcomes.

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.